1. Scrip
  2. >>Therapy Areas

Otsuka’s ADHD Contender Hits Mark In Phase III

Validation Of $250m Acquisition

 
• By Ian Haydock

Otsuka's novel ADHD therapy moves closer to a potential filing after meeting its endpoint in two Phase III trials, validating a past acquisition and further bolstering the Japanese firm's CNS prospects. 

ADHD
New ADHD Candidate Moves Ahead • Source: Shutterstock

In positive new top-line Phase III results in the CNS space, Otsuka Pharmaceutical Co. Ltd. said its oral serotonin-norepinephrine-dopamine triple re-uptake inhibitor centanafadine hit its primary endpoint in two trials in adult patients with attention-deficit hyperactivity disorder (ADHD).

The new data mark significant progress for the novel molecule and the company said it is now planning to discuss...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?